Results 131 to 140 of about 74,738 (274)

An In Vitro Study Simulating Prophylactic Anticoagulation in Haemophilia A and B

eJHaem, Volume 7, Issue 6, December 2026.
ABSTRACT Introduction Patients with haemophilia A (HA) and haemophilia B (HB) are at increased bleeding risk. A recent guidance document suggests considering pharmacological thromboprophylaxis on a case‐by‐case basis in these patients undergoing surgery at high‐risk of venous thromboembolism.
Nicoletta Riva, Kevin Vella, Kieron Hickey, Nigel Debattista, Carmel Grima, Denise Borg‐Aquilina, Liberato Camilleri, Jiong Jiong Guo, Alexander Gatt   +8 more
wiley   +1 more source

Disulfide bond status links the open and closed conformations of prothrombin

Protein Science, Volume 35, Issue 12, December 2026.
Abstract Emerging evidence indicates that structural changes in proteins can influence autoimmune recognition. Antibodies targeting the central blood coagulation protein, prothrombin, are frequently detected in patients with the autoimmune disorder, antiphospholipid syndrome.
Mark Schreuder, Diego Butera, Suresh Kumar, Nicola Pozzi, Philip J. Hogg   +4 more
wiley   +1 more source

The Thromboplastin Generation Test [PDF]

Journal of Clinical Pathology, 1953
R, BIGGS, A S, DOUGLAS
openaire   +2 more sources

The need for dried plasma—Still a national issue: Where are we and recommendations

Transfusion, EarlyView.
Anthony E. Pusateri, Shibani Pati, Toby A. Silverman, Roman Dudaryk, Joseph F. Rappold, Lisa Buckley, Andrew P. Cap, Jose A. Cancelas, Laurence M. Corash, G. Michael Fitzpatrick, Michael Ganio, Adam Gerber, Richard Gonzales, Jennifer M. Gurney, Ernest E. Moore, Hunter B. Moore, Vijayan Nair, Michael Policastro, Travis M. Polk, Jeffrey W. Shupp, Jason L. Sperry, Ralph R. Vassallo, Therese A. West, John B. Holcomb, Lester Martinez‐Lopez   +24 more
wiley   +1 more source

A Biweekly GLP‐1R Agonist Designed With Drug‐Free Intervals for Enhanced Efficacy, Receptor Homeostasis and Gastrointestinal Tolerability

Diabetes, Obesity and Metabolism, Volume 28, Issue 12, Page 11143-11177, December 2026.
ABSTRACT Aim To develop a next‐generation, longer‐acting, more‐clinical‐benefits agonist to achieve sustained efficacy with improved tolerability. Methods CT130 was designed from semaglutide. Binding affinity was validated via molecular dynamics and cellular assays.
Wei Ding, Qing Liu, Qiong Luo, Xiaojun Yao, Xingxing Fan   +4 more
wiley   +1 more source

Safety of Lowering the Platelet Transfusion Threshold Before Central Venous Catheterisation in Patients With Haematological Diseases

European Journal of Haematology, Volume 117, Issue 6, Page 1531-1540, December 2026.
ABSTRACT Introduction Central venous catheter (CVC) insertion is frequently required in patients with haematological diseases. Despite limited evidence, thrombocytopenia often prompts prophylactic platelet transfusion before catheterisation. Methods We conducted an observational before‐and‐after study including the first non‐tunnelled CVC insertion ...
Mathias Lazarevic Lindblad, Elin Pålsson, Vladimir Lazarevic, Leila Naddi, Ola Borgquist, Lars Nilsson, Maria Adrian, Björn P. Bark, Thomas Kander   +8 more
wiley   +1 more source

Activated Partial Thromboplastin Time Clot Waveform Analysis In Hemophilia A

Journal of Taibah University Medical Sciences, 2023
Maha Said, Amani Jabri, Ons Ghali, Fatma Ben Lakhal, Sarra Fekih Salem, Emna Gouider, Wijdene El Borgi   +6 more
doaj   +1 more source

Thrombotic Microangiopathy‐Like Phenotype in Patients With Infection‐Associated Disseminated Intravascular Coagulation Treated With Thrombomodulin Alfa

European Journal of Haematology, Volume 117, Issue 6, Page 1552-1561, December 2026.
ABSTRACT Despite disseminated intravascular coagulation (DIC) and thrombotic microangiopathy (TMA) sharing features of thrombocytopenia, organ dysfunction, and bleeding, the relationship between these two conditions remains unclear. We therefore conducted a post hoc analysis of post‐marketing surveillance data from Japan to evaluate the clinical ...
Naoki Takezako, Fumiyo Komatsu, Goichi Honda, Noriaki Kawano, Toshimasa Uchiyama, Kazuo Kawasugi, Seiji Madoiwa, Kei Suzuki, Yoshinobu Seki, Takayuki Ikezoe, Kohji Okamoto, Hideo Wada   +11 more
wiley   +1 more source

Identifying the silent deficiency: Severe Factor XI deficiency in an asymptomatic patient with isolated prolonged activated partial thromboplastin time—A case report

SAGE Open Medical Case Reports
Assessing a patient with a suspected bleeding disorder is a complex aspect of hematology. Prolonged activated partial thromboplastin time often indicates a coagulation factor deficiency or inhibitor and warrants detailed evaluation. Factor XI deficiency,
Awni Alshurafa, Mahmoud Draidi, Feryal Ibrahim, Shehab F. Mohamed, Mohamed A. Yassin   +4 more
doaj   +1 more source

How I Investigate Bleeding Disorders of Unknown Cause: Current Diagnostic Pathways and Gaps in Laboratory Investigation

International Journal of Laboratory Hematology, Volume 48, Issue 6, Page 1289-1297, December 2026.
ABSTRACT Bleeding disorder of unknown cause (BDUC) constitutes the largest group of patients presenting with a mild‐to‐moderate bleeding tendency in tertiary care settings. Their clinical bleeding phenotype is characterized by mucocutaneous bleeding, as well as bleeding following surgical challenges or childbirth, and is associated with impaired health‐
Dino Mehic, Faris Karaselimovic, Tim Dreier, Johanna Gebhart   +3 more
wiley   +1 more source